Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication

Author： De LaVega Alfonso J   Derk Chris T  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.18, Iss.1, 2009-01, pp. : 23-29

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

By  

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3467-3484

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip   Keel Christopher   Klavens Meghan   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

By Bruzziches Roberto  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1333-1344

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment

By  

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3486-3495

Bentham Science Publishers

Access to resources Recommend Favorite

Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

By Kendirci Muammer   Bivalacqua Trinity J   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 923-932

Informa Healthcare

Access to resources Recommend Favorite